Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • mpalegre
    Junior Member
    • Feb 2014
    • 8

    Using TopHat2 RNA-Seq Data IOn-Torrent

    Hi everyboy. I have a quick question about the "--library-type" option in the Tophat2. If the reads are from single end, RNA-seq (poly(A)) LIbrary using kit Ion Total RNA-Seq Kit v2 which options is correct. FR Unstranded? the another are -FR- First strand or FR-Second Strand. Can Anyone clarify me this?

    Thanks in advance
    Regards
  • cmbetts
    Senior Member
    • Jun 2012
    • 120

    #2
    From the manual for the kit, The Ion Adaptor Mix v2 constrains the
    orientation of the RNA in the ligation reaction such that hybridization with the Ion
    Adaptor Mix v2 yields template for sequencing from the 5′ end of the sense strand.

    So you'd want to use the fr-secondstrand option for mapping

    Comment

    • mpalegre
      Junior Member
      • Feb 2014
      • 8

      #3
      thanks so much

      Comment

      • mlou
        Junior Member
        • Jul 2013
        • 1

        #4
        I found this post helpful: http://onetipperday.blogspot.co.uk/2...pe-to-use.html

        Essentially I chose a few reads, BLAT to a genome and infer the library-type from the mapping result.
        Last edited by mlou; 12-09-2014, 01:07 PM.

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
          by SEQadmin2


          Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

          The systematic characterization of the human proteome has
          ...
          07-20-2026, 11:48 AM
        • SEQadmin2
          Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
          by SEQadmin2



          Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
          ...
          07-09-2026, 11:10 AM
        • SEQadmin2
          Cancer Drug Resistance: The Lingering Barrier to Rising Survival
          by SEQadmin2



          Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

          There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
          07-08-2026, 05:17 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, 07-24-2026, 12:17 PM
        0 responses
        26 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-23-2026, 11:41 AM
        0 responses
        20 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-20-2026, 11:10 AM
        0 responses
        28 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-13-2026, 10:26 AM
        0 responses
        38 views
        0 reactions
        Last Post SEQadmin2  
        Working...